A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 240 participants.

Also called NCT02324569

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 240 participants (enrolled count) (from the registry)
Sponsor
  • Takeda Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02324569
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02324569. Randomized; quadruple masking; primary purpose treatment. Start 2014-12-27 (actual); primary completion 2016-12-28 (actual). Results posted on 2019-02-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
SYR-472
Intervention (Drug)
Placebo
Lead sponsor
Takeda (class: industry)

Record details

Record id
cardio:ct-nct02324569
Content hash
3d470269b248997fcdc2dcd587acee9d58a811f25c5aa0d35f32b10939a0729e